Evaluation of LY573144 (lasmiditan) in a preclinical model of medication overuse headache
BACKGROUND: Medication overuse is a significant issue that complicates the treatment of headache disorders. The most effective medications for the acute treatment of migraine all have the capacity to induce medication overuse headache (MOH). Novel acute migraine-specific treatments are being developed. However, because the mechanism(s) underlying medication overuse headache are not well understood, it is difficult to predict whether any particular acute medication will induce MOH in susceptible individuals. LY573144 (lasmiditan), a 5-HT1F receptor agonist, has recently been shown to be effective in the acute treatment of migraine in phase 3 trials. The aim of this study is to determine whether frequent administration of lasmiditan induces behaviors consistent with MOH in a pre-clinical rat model.
METHODS: Sprague Dawley rats were administered six doses of lasmiditan (10 mg/kg), sumatriptan (10 mg/kg), or sterile water orally over 2 weeks and cutaneous allodynia was evaluated regularly in the periorbital and hindpaw regions using von Frey filaments. Testing continued until mechanosensitivity returned to baseline levels. Rats were then submitted to bright light stress (BLS) or nitric oxide (NO) donor administration and were again evaluated for cutaneous allodynia in the periorbital and hindpaw regions hourly for 5 hours.
RESULTS: Both lasmiditan and sumatriptan exhibited comparable levels of drug-induced cutaneous allodynia in both the periorbital and hindpaw regions, which resolved after cessation of drug administration. Both lasmiditan and sumatriptan pre-treatment resulted in cutaneous allodynia that was evoked by either BLS or NO donor.
CONCLUSIONS: In a pre-clinical rat model of MOH, oral lasmiditan, like sumatriptan, induced acute transient cutaneous allodynia in the periorbital and hindpaw regions that after resolution could be re-evoked by putative migraine triggers. These results suggest that lasmiditan has the capacity to induce MOH through persistent latent peripheral and central sensitization mechanisms.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:40 |
|---|---|
| Enthalten in: |
Cephalalgia : an international journal of headache - 40(2020), 9 vom: 25. Aug., Seite 903-912 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rau, Jill C [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
760I9WM792 |
|---|
| Anmerkungen: |
Date Completed 25.10.2021 Date Revised 25.10.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1177/0333102420920006 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM311589642 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM311589642 | ||
| 003 | DE-627 | ||
| 005 | 20231225142557.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1177/0333102420920006 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1038.xml |
| 035 | |a (DE-627)NLM311589642 | ||
| 035 | |a (NLM)32580575 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rau, Jill C |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evaluation of LY573144 (lasmiditan) in a preclinical model of medication overuse headache |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.10.2021 | ||
| 500 | |a Date Revised 25.10.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: Medication overuse is a significant issue that complicates the treatment of headache disorders. The most effective medications for the acute treatment of migraine all have the capacity to induce medication overuse headache (MOH). Novel acute migraine-specific treatments are being developed. However, because the mechanism(s) underlying medication overuse headache are not well understood, it is difficult to predict whether any particular acute medication will induce MOH in susceptible individuals. LY573144 (lasmiditan), a 5-HT1F receptor agonist, has recently been shown to be effective in the acute treatment of migraine in phase 3 trials. The aim of this study is to determine whether frequent administration of lasmiditan induces behaviors consistent with MOH in a pre-clinical rat model | ||
| 520 | |a METHODS: Sprague Dawley rats were administered six doses of lasmiditan (10 mg/kg), sumatriptan (10 mg/kg), or sterile water orally over 2 weeks and cutaneous allodynia was evaluated regularly in the periorbital and hindpaw regions using von Frey filaments. Testing continued until mechanosensitivity returned to baseline levels. Rats were then submitted to bright light stress (BLS) or nitric oxide (NO) donor administration and were again evaluated for cutaneous allodynia in the periorbital and hindpaw regions hourly for 5 hours | ||
| 520 | |a RESULTS: Both lasmiditan and sumatriptan exhibited comparable levels of drug-induced cutaneous allodynia in both the periorbital and hindpaw regions, which resolved after cessation of drug administration. Both lasmiditan and sumatriptan pre-treatment resulted in cutaneous allodynia that was evoked by either BLS or NO donor | ||
| 520 | |a CONCLUSIONS: In a pre-clinical rat model of MOH, oral lasmiditan, like sumatriptan, induced acute transient cutaneous allodynia in the periorbital and hindpaw regions that after resolution could be re-evoked by putative migraine triggers. These results suggest that lasmiditan has the capacity to induce MOH through persistent latent peripheral and central sensitization mechanisms | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Pain | |
| 650 | 4 | |a allodynia | |
| 650 | 4 | |a lasmiditan | |
| 650 | 4 | |a migraine | |
| 650 | 4 | |a stress | |
| 650 | 4 | |a sumatriptan | |
| 650 | 7 | |a Analgesics |2 NLM | |
| 650 | 7 | |a Benzamides |2 NLM | |
| 650 | 7 | |a Piperidines |2 NLM | |
| 650 | 7 | |a Pyridines |2 NLM | |
| 650 | 7 | |a Serotonin Receptor Agonists |2 NLM | |
| 650 | 7 | |a lasmiditan |2 NLM | |
| 650 | 7 | |a 760I9WM792 |2 NLM | |
| 650 | 7 | |a Sumatriptan |2 NLM | |
| 650 | 7 | |a 8R78F6L9VO |2 NLM | |
| 700 | 1 | |a Navratilova, Edita |e verfasserin |4 aut | |
| 700 | 1 | |a Oyarzo, Janice |e verfasserin |4 aut | |
| 700 | 1 | |a Johnson, Kirk W |e verfasserin |4 aut | |
| 700 | 1 | |a Aurora, Sheena K |e verfasserin |4 aut | |
| 700 | 1 | |a Schwedt, Todd J |e verfasserin |4 aut | |
| 700 | 1 | |a Dodick, David W |e verfasserin |4 aut | |
| 700 | 1 | |a Porreca, Frank |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cephalalgia : an international journal of headache |d 1981 |g 40(2020), 9 vom: 25. Aug., Seite 903-912 |w (DE-627)NLM012712523 |x 1468-2982 |7 nnns |
| 773 | 1 | 8 | |g volume:40 |g year:2020 |g number:9 |g day:25 |g month:08 |g pages:903-912 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1177/0333102420920006 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 40 |j 2020 |e 9 |b 25 |c 08 |h 903-912 | ||